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Definition: Primary biliary cirrhosis (PBC) and pri-
mary sclerosing cholangitis (PSC) are both
cholestatic liver diseases. A common feature of
these disorders is the accumulation of bile acids in
the liver and blood, presumably because of
decreased biliary secretion and reduced bile flow. 
Etiology: Etiology and pathogenesis of PBC and
PSC are still unknown. PBC is considered to be an
autoimmune disease [1]. Immunological mechanisms
may also be involved in PSC since there is an associ-
ation with ulcerative colitis [2] and autoantibodies
can be detected [3]. Furthermore, genetic factors
seem to play an important role in both diseases [3,4]. 
Therapy: Since the pathogenesis of both dis-
eases is unclear, there is no definite causal treat-
ment. However, ursodeoxycholic acid (UDCA) was
shown to be highly effective. Other drugs which
can be used alone or in combination with UDCA
are promising and might further improve the out-
come of the diseases. 
2.  Ursodeoxycholic acid
In 1981 the first observation that UDCA noticeably
improves liver function tests was made in patients
with chronic active hepatitis who underwent gall-
*Correspondence to: Prof. Ulrich LEUSCHNER
Medizinische Klinik II, Johann-Wolfgang Goethe Universität,
Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Email: U.Leuschner@em.uni-frankfurt.de
1.  Introduction
Keywords:  primary biliary diseases • ursodeoxycholic acid • immunosuppressants •
biliary cirrhosis • sclerosing cholangitis
Special  Article
•  Introduction
•  Ursodeoxycholic acid
- Mechanisms of action




•  Treatment of primary sclerosing cholangitis  
- Ursodeoxycholic acid
- Other medical therapies
- Endoscopic and surgical treatment
•  Extrahepatic manifestations of 
cholestatic liver diseases
•  New immunosuppressantsstone dissolution with UDCA [5]. These data were
confirmed in 1985 [6]. In the same year the first
results were published on the treatment of six
patients with PBC and 2 patients with PSC [7].
Since then, numerous clinical observations have
been published that support the notion that UDCA
is effective in cholestatic disorders and increasing
experimental evidence supports the use of UDCAin
these conditions [8].
UDCAis the 7β−epimer of chenodeoxycholic acid
(CDCA) and represents a small fraction of the normal
bile acid pool in humans [9]. During oral UDCA
administration, endogenous bile acids are replaced
from the bile acid pool and the proportion of UDCA
increases up to 50% [10]. UDCA is efficiently taken
up in the liver, conjugated primarily with glycine (and
to a lesser extent to taurine) and secreted into bile with
subsequent enterohepatic circulation [10]. 
2.1.  Mechanisms of action 
The exact mechanisms of action of UDCA in
cholestatic liver diseases are unknown. The favor-
able effects can be classified into: 
- reduced hydrophobic bile acid concentrations 
- stimulation of choleresis
- influence on signal transduction and bile acid
transporters
- hepatoprotective effects 
- immunomodulatory effects
2.1.1.  Replacement of toxic endogenous 
bile acids and stimulation of bile secretion. 
Influence on signal transduction and 
bile acid transporters
Under continuous oral treatment, UDCA becomes
the predominant bile acid in serum, liver tissue and
bile and replaces more hydrophobic (and therefore
toxic) bile acids [11]. A further increase in
hydrophilicity (e.g. caused by cholylsarcosine) is
not superior to UDCA monotherapy [12].
Therefore, inhibition of absorption of toxic bile
acids from the intestine and stimulation of excretion
seem to be more important [9]. The enhancement of
the biliary excretory capacity is caused by a stimu-
lation of vesicular exocytosis, which is mediated by
the activation of hepatocellular Ca2+, α-proteinki-
nase C and mitogen-activated protein kinases
[9,13]. A recently published paper suggests that
activation of intracellular signal transduction is
important for choleretic effects [14]. 
2.1.2.  Cytoprotective effects on hepatocytes and 
bile duct epithelial cells
The cytoprotective effects of UDCA seem to be
mediated through direct membrane stabilizing and
anti-apoptotic effects [9,15]. Membrane stabiliza-
tion is due to incorporation of UDCA into the more
apolar domain of the membrane [16,17]. Another
effect observed is reduction in mitochondrial mem-
brane permeability [17]. 
2.1.3.  Immunomodulatory effects 
Several reports suggest that UDCAhas some modula-
tory effects on immune functions. The expression of
MHC class I molecules is increased in cholestasis
which may activate cytotoxic T lymphocytes in PSC
and PBC. This might be prevented by UDCA since it
was demonstrated that UDCA down regulates the
expression of abnormal MHC class I molecules in
periportal hepatocytes and of MHC class II on cholan-
giocytes of PBC and PSC patients [9]. However, it is
more likely that the effects on MHC class I expression
are the result of improved cholestatic liver injury
rather than a direct immunosuppressive effect of
UDCA[8]. Furthermore, changes in the concentration
of circulating IgM, of activated T lymphocytes and of
IFN-γ were reported [18]. Taken together, the mode of
action of UDCAseems to be multifactorial. 
3.  Treatment of primary 
biliary cirrhosis
Up to now, several trials have been conducted eval-
uating drugs with different mechanisms of action,
but without convincing evidence of benefit. In addi-
tion many drugs have an unacceptable profile of
adverse effects. 
3.1.  Ursodeoxycholic acid in 
primary biliary cirrhosis
The first randomized controlled trial demonstrated in
1989 the therapeutic value of UDCA[19] which was
confirmed by many other studies [20-23]. UDCA
leads to an improvement in survival, slows down the
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liver transplantation [1]. Arecent study demonstrated
that patients receiving UDCA had a lower incidence
of major complications and lower medical care costs
compared to patients receiving placebo [24]. Based
on these studies, UDCA has been established as the
treatment of choice for PBC since it is safe and well
tolerated in a dosage of 5-25 mg/kg/d [25]. The rec-
ommended dosage in PBC is 13-15 mg/kg/d [25].
The only significant side effect is diarrhea, which
probably occurs in less than 5% of patients.
According to biochemical data and the Mayo risk
score, no further improvement is achieved when
higher doses are administered [25,26]. Less than 10
mg/kg/day seem to be not effective [27].
3.1.1.  Effect on laboratory values 
In all trials it was shown that even short term treat-
ment with UDCA leads to a marked improvement in
the serum markers of chronic cholestasis [28].
However, only 30 % of UDCA treated patients have
a complete normalization of their biochemical tests,
whereas 70% are incomplete responders [29]. Recent
evidence suggests that the effects of UDCA are not
primarily related to the stage of the disease [30] but
to the degree of cholestasis. Thus, a therapeutic
approach with a more powerful choleretic compound
might be more effective in those subjects and first
results of a prospective controlled pilot study with
sulindac support this hypothesis. Sulindac, a nons-
teroidal antiinflammatory drug with choleretic prop-
erties [31], could further improve liver bio-
chemistries in these patients, when given 100-300
mg per day, in combination with UDCA [32].
3.1.2.  Effect on survival
UDCA leads to a significant increase in survival in
most controlled trials [1]. This effect is especially
visible in studies with advanced disease (bilirubin >
1,4 mg/dl, and /or histological stage III, IV)[33].
Patients with PBC on UDCA have been followed
for a maximum of 12 years and the survival time of
these patients exceeded those of historical controls
[34]. In a recently published long term trial the ten
years survival on UDCAin 225 patients was higher
than that of untreated patients as predicted by the
Mayo model [35]. This suggests that the real bene-
fit from UDCA may be greater in early stages than
in later stages of the disease. 
The effects of UDCAin PBC were questioned in
a recently published meta-analysis which missed to
show a benefit in survival, number of transplanta-
tions or survival free of transplantation [36]. The
authors  evaluated 11 trials but, in 8 studies, data
were not well defined (UDCA-dosage, stage of the
disease, treatment time and definition in treatment
failure). Therefore, it is not possible to draw any
conclusions from this meta-analysis. In a second
meta-analysis, using the same 11 studies, the
authors demonstrated that the risk of death or need
for orthotopic liver transplantation (OLT) in the
UDCAgroup is statistically significantly lower than
in untreated patients [37]. 
3.1.3.  Effect on histology 
The effect of UDCA on liver histology has been
less conclusive and conflicting results have been
published. In some trials a benefit on liver histol-
ogy could not be observed [21,23,38,39].
Furthermore, improvement in histology, which was
seen in other studies, was only related to inflam-
mation without influence on liver fibrosis and bile
duct alterations [39-42]. However, in a recently
published trial, UDCA decreased the progression
rate to extensive fibrosis [43]. This possible bene-
fit of UDCA is supported by the observed antifi-
brotic effects in experimental trials [44]. 
3.1.4.  Effect on symptoms and 
portal hypertension
A beneficial effect on pruritus and fatigue as
observed by some groups [22,45-47] was not con-
firmed by others [21]. Improvement of liver enzymes
is probably not correlated with the amelioration of
pruritus [48]. Nevertheless pruritus improved in
patients with a complete normalization of cholestasis
[29]. Therapy with UDCAseems to reduce the onset
and severity of portal hypertension [49] and to lower
the risk of esophageal varices [50].
3.1.5.  Summary and conclusions
Ursodeoxycholic acid has been extensively evaluat-
ed and shown to improve liver biochemistries and
survival in patients with PBC. Although UDCA
slows the progression, it does not cure the disease
and as there are some patients who respond incom-
pletely to UDCA monotherapy with respect to their
100laboratory values, there is a need for new drugs or
combination therapies (Table 1).
3.2.  Immunosuppressants in 
primary biliary cirrhosis
Because PBC appears to be an autoimmune disease,
several immunosuppressive drugs have been tested
in randomized controlled trials [28]. However, so
far none has been shown to be of great benefit and
their use is limited due to their side effects.
3.2.1.  Steroids in primary biliary cirrhosis
Although prednisolone was the first immunosup-
pressive therapy to be used in PBC, only one small
controlled trial was published [51]. The results
were rather disappointing and steroids as a
monotherapy can not be recommended [52,53].
Recently, it has been shown that short-term admin-
istration of methylprednisolone increases cholic
acid synthesis and turnover, as well as intestinal
production of toxic deoxycholic acid [54]. This
could limit the therapeutic value of steroids.
Nevertheless the combination of corticosteroids
with UDCA seems to be superior to UDCA
monotherapy [55,56]. As long term or even life
time treatment is necessary in patients with PBC,
glucocorticoid-induced side effects like osteoporo-
sis are a major problem. 
Budesonide in primary biliary cirrhosis
Budesonide is a topical non-halogenated glucocor-
ticoid with a high first pass effect of more than
90% resulting in fewer systemic side effects [57].
In a controlled, double blind trial a 2 year combi-
nation therapy with budesonide (2 x 3 mg/day) and
UDCA improved laboratory values and histology
in patients with early stages of the disease [58]. In
another trial budesonide was less effective and had
more side effects [59]. However, this was an
uncontrolled one year study which included
patients with late stage PBC and who were incom-
plete responders to UDCA monotherapy.
Furthermore, it is possible that the advantage of
the high first pass effect of budesonide is abol-
ished in patients with liver cirrhosis and portosys-
temic shunts. Thus, it is too early to conclude
whether budesonide is effective or not, especially
when subjects with end stage liver disease are
included.
3.2.2.  Azathioprine in primary biliary cirrhosis
There are only a few trials with azathioprine as a mo-
notherapy. No improvement on survival was observed
[60-62]. However, in one trial azathioprine in combi-
nation with prednisolone and UDCA had a beneficial
effect [63]. Furthermore, azathioprine may allow to re-
duce the glucocorticoid dosage to prevent side effects.
3.2.3.  Methotrexate in primary biliary cirrhosis
There are contradictory studies concerning the treat-
ment of PBC with methotrexate (MTX). With
respect to liver histology the degree of inflammation
and bile duct injury improved in some patients but
the degree of liver fibrosis and the histological stage,
which are the most important parameters, did not
improve or even continued to progress [64].
Furthermore, the use of MTX is limited due to its
toxic side effects. Patients with PBC receiving
methotrexate 15 mg/wk are more susceptible to
interstitial pneumonitis (up to 15%) than patients
with psoriasis or rheumatoid arthritis [65]. With a
low dose of MTX (7,5 mg/week) side effects were
prevented but the treatment was ineffective [66]. The
minimal effective dose for MTX in PBC seems to be
12,5 – 20 mg/week [67]. Methotrexate might be ben-
eficial in patients with early stage disease [68,69].
However, these two studies were uncontrolled trials. 
In most studies combination-therapy of UDCA
with MTX did not show any additional benefit to
that achieved by UDCA alone [70-72]. Only in one
trial symptoms and laboratory values improved.
Histology and the natural history were not investi-
gated [73]. At present MTX should be avoided or
very carefully recommended. 
3.2.4.  Cyclosporine A in 
primary biliary cirrhosis
Treatment with cyclosporine has been disappointing
because of limited efficacy and a marked toxicity
[74]. The modest improvement in liver function tests,
histology and survival are counterbalanced by the
development of hypertension in some and worsening
renal function in most patients [75]. Cyclosporine A
(CSA) may be helpful in selected cases.
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3.3.1  Colchicine
An alternative approach to therapy of PBC is the
prevention of fibrosis using agents that inhibit colla-
gen formation [76-78]. Colchicine is a safe and inex-
pensive drug with a long term effect on the biochem-
ical parameters of disease activity. However, compli-
cations of cirrhosis, deaths and transplantations were
not reduced [78,79]. The combination of UDCA and
colchicine lead to further improvement in laboratory
values [80,81]. This was not confirmed by others
[48,82] and the influence on the effect on liver his-
tology was not convincing [48,83]. A triple therapy
with colchicine, MTX and UDCA may be beneficial
for patients who incompletely respond to UDCA
[84]. Colchicine in addition to UDCAwas less effec-
tive than treatment with MTX and UDCA [85].
3.3.2.  Bezafibrate
In a preliminary study the combination with UDCA
and bezafibrate was superior to UDCAalone with res-
pect to alkaline phosphatase (AP) and IgM [86]. Side
effects were not observed. In another trial monothera-
py with bezafibrate showed a significant reduction in
laboratory values which was similar to that seen with
the combination of UDCA and bezafibrate [87]. It is
believed that bezafibrate stimulates phospholipid
excretion into bile. 
3.3.3.  D-Penicillamine and chlorambucil
D-Penicillamine is not recommended in PBC as
efficacy was lacking and major side effects were
observed [88,89]. In a randomized trial with chlo-
rambucil a benefit on laboratory values, especially
on serum bilirubin was observed [90]. Although the
patients were treated with a suboptimal dose, all of
them developed bone marrow suppression.
Therefore the drug cannot be recommended.
3.3.4.  Summary
In summary all patients with PBC should be treated
with UDCA at a dosage of 13-15 mg/kg/d. Patients
incompletely responding after 6-12 months should
be treated with a combination therapy (Table 1). 
4.  Treatment of primary sclerosing
cholangitis
4.1.  Treatment with ursodeoxycholic acid
Because treatment with UDCA in PBC was effec-
tive and well tolerated several studies were con-
ducted in PSC [91]. Similar to PBC all studies
resulted in a marked reduction of cholestasis [92-
96], and even bilirubin, which is a strong prognos-
tic marker, improved. Thus, UDCAis the treatment
of choice in all stages of PSC. Patients should be
treated as early as possible, and prolonged or per-
manent therapy must be recommended, as no
major side effects have been observed [91]. The
recommended dosage of UDCA is 15-20 mg/kg.
Dosages less than 10 mg/kg seem to be without
effect [96,97]. 
There are only limited data on histological
changes during UDCA therapy. Most studies showed
the cellular infiltration of the portal triads improved
102
Table 1  Drugs for monotherapy and combination-therapy in primary biliary cirrhosis




•  13-15 mg/kg/day 
•  3x daily or in one single dose 
•  lifelong therapy 
UDCA + 
+ prednisone/prednisolone 
13-15 mg/kg/day  
+ 10-15 mg/day 
+ budesonide  + 3x3 mg/day 
+ azathioprine  + 50-100 mg/day 
Treatment of patients  
who are incomplete 
responders to UDCA 
monotherapy 
+ methotrexate  + 7.5 mg/week whereas all other changes were not significantly
influenced [92,94]. Improvement was more pro-
nounced with higher dosages of UDCA [96]. There
was no influence of UDCAon the histologic progres-
sion when patients with an histological advanced dis-
ease were treated [93,98]. Up to now no study had
sufficient power to assess the effects of UDCA on
survival. Treatment of pruritus, osteoporosis and vita-
min deficiencies due to steatorrhea should follow the
general guidelines [99] (see below). Improvement of
symptoms was observed in some individuals on
UDCA therapy but not in all subjects [93,95]. 
4.2  Other medical therapies
Attempts have been made to treat patients with
immunosuppressive, antiinflammatory and antifi-
brotic agents. None of these drugs could stop the
natural course of the disease. On the other hand,
treatment may even be harmful because of the high
frequency of bacterial cholangitis. 
4.2.1.  Steroids in primary sclerosing cholangitis
Patients with ulcerative colitis (UC) who are on
steroids can develop PSC, or experience progression
of the disease. Thus, monotherapy with corticos-
teroids is not effective [91]. No benefit was seen in a
one year uncontrolled study, where patients with late
stage PSC were treated with budesonide. Serum AP
and aspartate amino transferase levels improved,
while serum bilirubin concentrations increased. In
addition a significant improvement in portal inflam-
mation was noted, whereas the degree of fibrosis and
the stage of the disease were not significantly affect-
ed [100]. Minor effects were observed with pred-
nisone in combination with UDCA when compared
with the combination of budesonide and UDCA
[101]. Positive results were also obtained with the
triple therapy of UDCA, prednisolone and azathio-
prine (decrease in liver enzymes) [102]. However,
the benefit of such a combination therapy has to be
confirmed in a long term trial with a larger group and
a more detailed description of the histological status. 
4.2.2.  Additional drugs
Uncontrolled and controlled trials and case reports
were published with azathioprine [103], cyclosporine
A [104], methotrexate [105,106], tacrolimus [107],
colchicine [108,109] and pentoxifylline [110].
Recently a combination therapy with UDCA and
sulphasalazine has been performed in three
patients with PSC. In this report the combination
therapy seems to be superior to UDCA monother-
apy [111]. A study with nicotine was not effective.
In this pilot trial 75 % of patients suffered from
severe side effects which led to the discontinua-
tion of the study [112]. Thus, at present none of
these drugs can be recommended as a monothera-
py. It is very likely, that with a better understand-
ing of the underlying pathophysiology, additional
new molecules with different modes of action will
be introduced.
4.3.  Endoscopic and surgical treatment
Dominant stenoses of the bile ducts are common
in PSC. In a 12 year prospective trial on the effect
of UDCA, 28/96 patients developed a progressive
stenosis of major bile ducts [113]. UDCA
monotherapy was unable to improve the trans-
plant free survival over 2 years [93], but UDCA
plus endoscopic dilatation of duct stenoses did
[114]. This is to be expected since stenoses are
not likely to improve on medical treatment.
Therefore, frequent endoscopic approaches are
necessary to manage this complication [114].
Beside repeated dilatations, intermittent stenting
or nasobiliary catheter perfusion are additional
options in the treatment of biliary stenosis. Thus,
endoscopic retrograde cholangiography (ERC) is
not only the gold standard for diagnosing PSC but
also an important tool in the management of the
disease.
Dominant strictures may also be managed surgi-
cally by dilatation or choledochojejunostomy.
However, the procedure is reserved for patients
with an early histological stage and symptomatic
extrahepatic or perihilar strictures. There is no ben-
efit for patients with a more advanced disease
[115]. Surgical intervention may complicate future
liver transplantation [116].
4.4.  Cholangiocarcinoma
Patients with PSC have a significantly increased
risk to develop cholangiocarcinoma (CC) [114].
The mean 10-year mortality rates for CC is 25%
[117]. In a large multicenter study from Sweden
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patients with PSC, followed for 63 months [118].
Furthermore, CC can be detected in up to 20 % of
explanted livers [119]. Alcohol consumption is an
additional risk factor for developing CC in PSC.
There is no correlation between the course of
PSC and the development of CC [120]. The inci-
dence of cholangiocarcinoma was higher in
patients with PSC and inflammatory bowel dis-
ease than in patients with PSC only [117]. At
present it is unclear whether treatment with
UDCA will influence the development of bile
duct carcinoma [114].
4.4.1.  Diagnosis and therapy of 
cholangiocarcinoma
The diagnosis of cholangiocarcinoma in PSC is
difficult because endoscopic brush cytology, biop-
sies and imaging are not reliable. The serum levels
of carbohydrate antigen (gastrointestinal cancer
antigen, CA 19-9) can rise temporarily in associa-
tion with a biochemical relapse of PSC, resulting in
insufficient sensitivity and specificity [120-122].
As CA 19-9 and carcinoembryonic antigen (CEA)
are not helpful in identifying patients with prema-
lignant changes who would benefit from surgery
[123], their prognostic value is limited. The detec-
tion of K-ras mutations and p53 dysfunction seems
to be promising [124,125].
With advances in surgical techniques, the num-
ber of curative resections for hilar cholangiocarcino-
ma has increased. However, the recurrence rate after
curative resection is high. There is no established
adjuvant therapy. CC is a highly resistant tumor and
unresponsive to driamycin, mitomycin C and cis-
platin [126]. The benefit of liver transplantation for
patients with clinically apparent cholangiocarcino-
ma is extremely poor. However, in patients with a
microscopic tumour detected in the explanted liver,
survival is similar to those transplanted with PSC
without cholangiocarcinoma [127]. Because of the
high recurrence rate and lack of positive prognostic
variables, transplantation should be used reluctantly
as a treatment for cholangiocarcinoma [128].
Transplantation in combination with preoperative
irradiation and chemotherapy seems to be associat-
ed with prolonged disease-free intervals and an
improved overall survival in highly selected patients
with early-stage cholangiocarcinoma [129]. 
4.5.  Primary sclerosing cholangitis 
and colorectal cancer
80% of patients with PSC suffer from ulcerative
colitis (UC) which is often mild or even asympto-
matic [114]. Interestingly the severity of UC
increases within the first years after liver transplan-
tation [127,130], and proctocolectomy does not
affect the progression of PSC [131]. PSC seems to
be an independent risk factor for the development
of colonic dysplasia and of colon carcinoma in
patients with UC [132]. This risk is further
increased in subjects with PSC and UC after liver
transplantation. Therefore, repeated colonoscopies
are strongly recommended in these patients [133].
Results of a recently published trial showed that
UDCA therapy was associated with a decreased
prevalence of colonic dysplasia in patients with
PSC [134]. Further trials are needed to confirm
these results.
5.  Extrahepatic manifestations of
cholestatic liver diseases
5.1.  Pruritus
Patients with chronic cholestatic liver diseases fre-
quently suffer from pruritus. Pruritus reduces life
quality considerably and in severe cases even liver
transplantation can be indicated. Because the patho-
genesis of pruritus is unknown, treatment is not
based on scientific evidence but on empirical
knowledge [135] (Table 2). Considering the litera-
ture accumulation of toxic bile acids and an
increase of pruritogenic substances seem less
important. More recent findings suggest that an
increase in neurotransmission, mediated by endoge-
nous opioid agonists, may be responsible for the
development of pruritus [135]. 
5.1.1.  Treatment
Although bile acids seem to be less important in the
pathogenesis of pruritus, cholestyramine, a non-
absorbable bile acids binding anion exchange resin,
is effective in more than 90% [136]. In cases where
patients do not tolerate the side effects like bad
taste, bloating, diarrhea and constipation, colestipol
can be used. Patients in whom cholestyramine is not
104effective, treatment with enzyme-inductors such as
rifampicin [137] phenobarbital [138] and s-adeno-
syl-methionine (SAMe) [139] may be helpful. The
weak effects of antihistamines are likely to be due
to their sedation [140].
As mentioned above, disturbances in the neuro-
transmission/neuromodulation of the central nerv-
ous system seem to be involved in the pathogenesis
of pruritus. Potent opiate antagonists, such as
nalmefene [141], naltrexone [142], and naloxone
[143],  are effective in 50 – 60 % of the patients
[135]. Other neurotransmitter-systems, such as
serotonin, might also be involved in the pathogene-
sis of pruritus. Some authors suggest that the 5HT3
serotonin antagonist ondansetron may ameliorate
pruritus [135,144]. However, further investigations
are needed to determine whether specific serotonin
receptor subtype ligands have a place in the treat-
ment of pruritus. 
5.2.  Fatigue
Fatigue affects up to two-thirds of PBC patients, but
its etiology remains obscure [145]. Like pruritus it
may be centrally mediated [135] since increased
serotonergic neurotransmission in the central nerv-
ous system contributes to fatigue [146,147]. There
are no convincing data about the efficacy of UDCA
[1,22,93] or other drugs. A benefit due to antioxi-
dant therapy has to be further investigated [148].
5.3.  Osteoporosis
Osteoporosis is a frequent complication in cholesta-
tic liver diseases and is present in almost all patients
with end stage liver disease [149]. Its pathogenesis
is not well understood. Osteoporosis is more fre-
quently seen in PBC than in PSC [150], although
factors specifically related to PBC have not been
defined [151]. Dual-energy X-ray absorptiometry is
the method of choice for evaluating and monitoring
osteoporosis [152].
Risk factors for the development of osteoporo-
sis in biliary liver diseases are not well defined.
The role of disease severity [153], vitamin D
receptor genotypes in PBC, cholestasis itself and
Sjögren syndrome are currently discussed [154].
Inflammatory bowel disease in combination with
PSC may or may not be an additional risk factor
[150].
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Table 2  Recommendation for the treatment of pruritus
ursodeoxycholic acid  12-15 mg/day 
cholestyramine  4-16 g/day in increasing dosage 
first line 
colestipol  5-30 g/day 
 
naloxone  2-3x0.4 mg/day 
naltrexone  50 mg/day orally 
second line 
ondansetron  3x4-3x8 mg/day orally 
 
rifampicin  300-500 mg/day up to 10 mg/kg/day 
metronidazole  3x250 mg/day for one week 
third line 
2,6-di-isopropylphenole  up to 15 mg/day 
 
plasmapheresis  3x/week,  
after that once every two weeks 
fourth line 
liver transplantation  in cases which are refractory  
to treatment 5.3.1.  Treatment
No therapy has shown to be satisfactory for meta-
bolic bone disease associated with cholestatic liver
disease (Table 3). In an early stage physical exer-
cise and maintaining adequate serum vitamin D
levels and calcium intake may be sufficient.
Monitoring of dietary intake of calcium and vitamin
D is reasonable and the threshold for initiating sup-
plementation should be low [155]. The results on
treatment with calcitonin monotherapy are contro-
versial. Whereas some authors could show a bene-
fit [156], the majority was unable to find an signif-
icant improvement [157]. Probably a combination
with vitamin D (1,25-dihydroxyvitamin D) and cal-
cium is effective [158]. UDCA does not seem to
have an influence on osteoporosis [150,159].
In subjects in menopause and with low bone
mineral density, estrogens are the standard treat-
ment to prevent osteoporosis [160]. Unfortunately
there are little data on estrogen therapy and PBC,
but it seems to be safe and effective [161]. Today in
postmenopausal patients biphosphonates (alen-
dronate) are the first choice of treatment [160], but
with respect to PBC, results are controversial [162].
In a recently published trial, cyclical etidronate
alternated with calcium could not improve bone
density [163]. However, PBC patients treated with
prednisolone seemed to benefit [164].
5.4.  Steatorrhea
In cholestatic liver diseases steatorrhea can occur
for three reasons: when bile acid concentration in
the duodenum is below the critical micellar concen-
tration, micelle formation and fat absorption are
reduced. In patients with PBC, sicca syndrome is
accompanied by a decreased secretion of pancreatic
enzymes and in some patients celiac disease devel-
ops [165,166]. For treatment, fat intake should not
exceed 20% of the total energy intake. In severe
cases middle chain triglycerides can be effective.
Deficiencies in fat soluble vitamins A, D, E and K
are seldom but have to be expected in manifest steat-
orrhea and should be supplemented by intramuscu-
lar injections. Furthermore, pancreatic enzymes can
be administered in high dosage (Table 4).
6.  New immunosuppressants
During the past 50 years, many immunosuppressive
drugs have been described. Eventually, the mecha-
nisms of action were found to fall into five groups:
(i) regulators of gene expression; (ii) alkylating
agents; (iii) inhibitors of de novo purine synthesis;
(iv) inhibitors of de novo pyrimidine synthesis; and
(v) inhibitors of kinases and phosphatases. Most of
the new immunosuppressive drugs have been
developed for organ transplantation and more
recently for autoimmune diseases [167]. Two of
these drugs which might be interesting candidates
for the treatment of PBC and PSC are tacrolimus
(FK 506) and mycophenolate mofetil (MMF).
However, their therapeutic use is often limited, due
to their toxic side effects like bone marrow sup-
pression, which can be observed in many patients.
Tacrolimus (FK506), a metabolite of an actino-
mycete Streptomyces tsukubaensis, was shown to
be immunologically effective. Adverse side effects
106
Table 3  Recommendation for the treatment of osteoporosis
•  well balanced nutrition, physical activity, muscle building 
 
•  vitamin D3 
 
additionally calcium  
500-5000 IE/day orally  
or 100,000 IE/mo. i.m. 
1000-1500 mg/day 
•  calcitonin monotherapy   only in low calcium diet 
•  estrogens  0.6 mg/day                           side effect: cholestasis 
•  biphosphonates 
alendronate 
etidronate 
     followed by calcium 
 
10 mg/day 
1 x 400 mg  for two weeks 
500 mg  for 76 days 
 of the drug include neurotoxicity and nephrotoxici-
ty [168]. Extensive efforts in identifying com-
pounds with an improved therapeutic utility may
lead to the design of safer FK506-related immuno-
suppressants [169]. Sirolimus is structurally related
to the immunosuppressive agent tacrolimus, and
retains a pharmacokinetic and drug interaction pro-
file similar to cyclosporine and tacrolimus [170]. It
is the latest pharmaceutical agent to complete phase
III trials, acts to inhibit IL-2 driven lymphocyte pro-
liferation and reduces the risk of acute rejection to
below 20% [171]. However, the molecule causes
severe hyperlipidemia, and the long-term conse-
quences both on the pathogenesis of cardiovascular
disease and on lipid-associated renal injury have yet
to be determined [172]. 
MMF was initially derived from cultures of
Penicillium spp. It is an immunosuppressive drug
which appears to be free of side effects and longer
treatment could probably be justified. The drug is
currently the leading candidate for replacement of
azathioprine [173]. Based on the experience in
clinical trials the recommended dosage is 2 g/day.
Two patients with PBC were treated with a combi-
nation of MMF 2 g and UDCA 1 g daily for 12
months. Both were incomplete responders to
UDCAmonotherapy. Adecrease in elevated serum
alkaline phosphatase levels to values close to the
upper limit of normal, and an almost complete dis-
appearance of the chronic inflammatory cell infil-
trate, was observed without significant adverse
events [174].
There are many other drugs which are potential-
ly effective in primary biliary liver diseases. These
include new regulators of gene expression, alkylat-
ing agents, inhibitors of de novo purine or pyrimi-
dine synthesis and inhibitors of kinase and phos-
phatases. However, there is no or very limited expe-
rience with these drugs [28].
There are no data on the treatment of primary
biliary liver diseases with cyclophosphamide.
However, in subjects with autoimmune hepatitis,
one study succeeded to induce and to maintain
remission, using a combination of a tapering dose
of corticosteroids and 1-1.5 mg/kg body-weight
cyclophosphamide [175]. The dosage used in this
12 year trial was much lower than that used in other
diseases and only minor side effects were observed.
Therefore, cyclophosphamide might be an alterna-
tive in patients with PBC or PSC.
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Table 4  Treatment of steatorrhea and vitamin deficiencies
•  reduction of fat intake to 40-50-(30) g/day 
•  middle chain triglycerides (MCT) 
•  lowering cholestyramine dosage 
•  glutenfree diet 
steatorrhea 
•  pancreatic enzymes 
 
vitamin A  25000-50000 IE i.m., 3x/week  
or 3x25000 IE/week 
vitamin K  10 mg/mo. i.m. 
vitamin E  100-400 mg α-tocopherol/mo. i.m. 
or 10-20 mg/day 
vitamin D3  500-5000 IE/day oral  
or 100000 IE/mo. i.m. 
vitamin deficiencies 
calcium  100-1500 mg/day 
 
zinc deficiencies  substitution sometimes necessary The results of the only trial with chlorambucil
for the treatment of PBC were not convincing [90].
Fludarabine is an effective treatment for subjects
with chronic lymphocytic leukemia which do not
respond to initial treatment with chlorambucil.
Pranlukast is a leukotriene antagonist known to
suppress eosinophil infiltration in atopic dermatitis
or bronchial asthma. This drug was tried in PBC
which is also characterized by eosinophil infiltrates
in the portal tract. Treatment with 450 mg/day
resulted in a significant improvement of laboratory
values [176]. Cladribine is a nucleoside analog
with specific antilymphocytic activity that has
been used in patients with autoimmune diseases. In
four patients with PSC (stages I and II) the drug
was well-tolerated. Cladribine decreased the hepat-
ic lymphocytic inflammation in early-stage PSC
without any symptomatic, biochemical, or radio-
logic improvements. Further studies  with long-
term follow-up are needed to assess if this anti-
inflammatory effect can modify the progression of
disease [177].
The novel synthetic immunosuppressive com-
pound FTY 720 has a different mode of action as
compared to other immunosuppressive drugs. It
reduces peripheral lymphocytes. This mechanism
potentiates the immunosuppressive effect when
combined with other immunosuppressants like
tacrolimus [178]. Further studies are being carried
out to determine its effect after organ transplanta-
tion or treatment of autoimmune liver diseases.
Monoclonal antibody therapy is an exciting new
development. Anti-interleukin-2 receptor antibod-
ies might constitute a safe and efficient addition to
the immunosuppressive induction regimen follow-
ing OLT [173,179]. Anti-CD3 antibodies are also
under current investigation. However, the benefit of
these drugs has to be proven in further trials. Gene
transfer and epithelial cell transplantation as well as
hepatocyte transplantation technologies play an
important role in the development of new therapeu-
tic concepts for liver diseases. Most of these proce-
dures and techniques are still experimental or have
been applied to a small number of patients only.
The treatment of the overlap syndromes between
primary biliary liver diseases and autoimmune hep-
atitis is still experimental and currently there is no
accepted therapy [180,181]. 
In summary, the development of new drugs offer
the opportunity to use combinations that block dif-
ferent pathways of immune activation. In addition
drugs with different toxicity profiles can be select-
ed in order to reduce the dosage of each drug. Until
now, OLT remains the final solution in the treat-
ment of primary cholestatic liver diseases and new
immunosuppressive regiments are likely to further
improve survival rates after transplantation.
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